E126: Risk Signals, JAKs, and SELECTIVE-ity
About this episode
The episode discusses a post hoc study of upadacitinib trials in rheumatoid arthritis, exploring the implications of JAK inhibitors.
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
More episodes of The Evidence Based Rheumatology Podcast
- E134: Brepocitinib in Dermatomyositis (VALOR)
- E133: Obinutuzumab for SLE (ALLEGORY)
- E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
- E131: A Sham-Controlled Sham of a Trial: RESET-RA
- E130: Telitacicept for SLE
- E129: Long Term Routine Laboratory Monitoring in RA
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.